Generation of Bispecific Antibodies by Functionalized Poly-ADP-Ribose Polymers.
Hyo Sun KimYong ZhangPublished in: Current protocols (2023)
Bispecific antibodies have drawn considerate research interests for therapeutic development. Numerous genetic and chemical methods are established to produce bispecific antibodies with varied formats. This protocol describes a novel approach to the synthesis of bispecific antibodies by utilizing chemically functionalized poly-ADP-ribose polymers derived from post-translational poly-ADP-ribosylation. Basic Protocol 1 includes experimental procedures for expressing and purifying recombinant full-length human poly-ADP-ribose polymerase 1 (PARP1) as well as monoclonal antibodies targeting T-cell CD3 and breast cancer tumor-associated human epidermal growth factor receptor 2 (HER2) molecules. Basic Protocol 2 details methods for enzymatic preparation of functionalized poly-ADP-ribose polymers by PARP1 and chemical conjugation of antibody molecules for bispecific antibody production. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Expression and purification of PARP1 and antibodies Basic Protocol 2: PARP1 auto-modification and antibody conjugation.
Keyphrases
- randomized controlled trial
- epidermal growth factor receptor
- dna damage
- dna repair
- endothelial cells
- quantum dots
- molecularly imprinted
- poor prognosis
- tyrosine kinase
- induced pluripotent stem cells
- gene expression
- nitric oxide
- oxidative stress
- hydrogen peroxide
- pluripotent stem cells
- long non coding rna
- cancer therapy